FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915209213> ?p ?o ?g. }

• W2915209213 endingPage "152877" @default.
• W2915209213 startingPage "152877" @default.
• W2915209213 abstract "Melanin plays a crucial role in protecting human skin against exposure to ultraviolet (UV) radiation. However, its overproduction induces hyperpigmentation disorders of the skin. To investigate effects of phenylethyl resorcinol as one resorcinol derivative on melanogenesis and its mechanisms using B16F10 mouse melanoma cells and human epidermal melanocytes. Effects of phenylethyl resorcinol on melanogenesis and its mechanism of action were examined using several in vitro assays (i.e., cell survival, melanin content, cellular tyrosinase activity, real-time PCR analysis, luciferase-reporter assay, Western blot analysis, and ELISAs for cyclic AMP (cAMP), protein kinase A (PKA), cAMP response element binding (CREB) protein, and mitogen-activated protein kinases (MAPKs)). Phenylethyl resorcinol reduced both melanin content and tyrosinase activity in these cells. Phenylethyl resorcinol also suppressed tyrosinase activity in cell-free tyrosinase enzyme assay. Although phenylethyl resorcinol decreased mRNA levels of tyrosinase and tyrosinase-related protein (TRP)-2, it did not affect mRNA levels of melanogenic gene microphthalmia-associated transcriptional factor (MITF) or TRP-1. Phenylethyl resorcinol had no effects on cAMP signaling or NF-κB signaling based on results of cyclic AMP response element (CRE)-luciferase reporter assay, cAMP production, protein kinase A (PKA) activity, Western blot assays for phosphorylated CRE-binding protein (CREB), NF-κB-luciferase reporter assay, and Western blot assays for phosphorylated NF-κB. However, phenylethyl resorcinol induced activation of activator protein-1 (AP-1) signaling. Specifically, phenylethyl resorcinol increased AP-1 reporter activity and increased phosphorylation of p44/42 MAPK, but not p38 MAPK or c-Jun N-terminal kinase (JNK). MEK1/2 and Src, upstream molecules of p44/42 MAPK were also phosphorylated by phenylethyl resorcinol. In addition, phenylethyl resorcinol-induced decreases in melanin content, tyrosinase activity, and MITF protein levels were attenuated by PD98059, a p44/42 MAPK inhibitor. These data indicate that the anti-melanogenic activity of phenylethyl resorcinol is mediated by activation of p44/42 MAPK, indicating that phenylethyl resorcinol may be a potential therapeutic agent for treating hyperpigmentation skin disorders." @default.
• W2915209213 created "2019-03-02" @default.
• W2915209213 creator A5001534001 @default.
• W2915209213 creator A5024468901 @default.
• W2915209213 creator A5031442900 @default.
• W2915209213 creator A5031787700 @default.
• W2915209213 creator A5036223616 @default.
• W2915209213 creator A5039964623 @default.
• W2915209213 creator A5041433551 @default.
• W2915209213 creator A5069435195 @default.
• W2915209213 creator A5085943012 @default.
• W2915209213 creator A5091626518 @default.
• W2915209213 date "2019-05-01" @default.
• W2915209213 modified "2023-10-16" @default.
• W2915209213 title "p44/42 MAPK signaling is a prime target activated by phenylethyl resorcinol in its anti-melanogenic action" @default.
• W2915209213 cites W1550461747 @default.
• W2915209213 cites W1839739904 @default.
• W2915209213 cites W1924695814 @default.
• W2915209213 cites W1947791771 @default.
• W2915209213 cites W1968873996 @default.
• W2915209213 cites W1979077842 @default.
• W2915209213 cites W1980355770 @default.
• W2915209213 cites W1982635732 @default.
• W2915209213 cites W1982787062 @default.
• W2915209213 cites W1995989612 @default.
• W2915209213 cites W2010684135 @default.
• W2915209213 cites W2015402128 @default.
• W2915209213 cites W2016791486 @default.
• W2915209213 cites W2027161175 @default.
• W2915209213 cites W2043584813 @default.
• W2915209213 cites W2051807533 @default.
• W2915209213 cites W2059658443 @default.
• W2915209213 cites W2112467050 @default.
• W2915209213 cites W2126229360 @default.
• W2915209213 cites W2136861424 @default.
• W2915209213 cites W2162730446 @default.
• W2915209213 cites W2164048042 @default.
• W2915209213 cites W2167048006 @default.
• W2915209213 cites W2182083146 @default.
• W2915209213 cites W2439931297 @default.
• W2915209213 cites W2587414694 @default.
• W2915209213 cites W2606645117 @default.
• W2915209213 cites W2795865937 @default.
• W2915209213 doi "https://doi.org/10.1016/j.phymed.2019.152877" @default.
• W2915209213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30849679" @default.
• W2915209213 hasPublicationYear "2019" @default.
• W2915209213 type Work @default.
• W2915209213 sameAs 2915209213 @default.
• W2915209213 citedByCount "14" @default.
• W2915209213 countsByYear W29152092132019 @default.
• W2915209213 countsByYear W29152092132020 @default.
• W2915209213 countsByYear W29152092132021 @default.
• W2915209213 countsByYear W29152092132022 @default.
• W2915209213 countsByYear W29152092132023 @default.
• W2915209213 crossrefType "journal-article" @default.
• W2915209213 hasAuthorship W2915209213A5001534001 @default.
• W2915209213 hasAuthorship W2915209213A5024468901 @default.
• W2915209213 hasAuthorship W2915209213A5031442900 @default.
• W2915209213 hasAuthorship W2915209213A5031787700 @default.
• W2915209213 hasAuthorship W2915209213A5036223616 @default.
• W2915209213 hasAuthorship W2915209213A5039964623 @default.
• W2915209213 hasAuthorship W2915209213A5041433551 @default.
• W2915209213 hasAuthorship W2915209213A5069435195 @default.
• W2915209213 hasAuthorship W2915209213A5085943012 @default.
• W2915209213 hasAuthorship W2915209213A5091626518 @default.
• W2915209213 hasConcept C104317684 @default.
• W2915209213 hasConcept C107538193 @default.
• W2915209213 hasConcept C11960822 @default.
• W2915209213 hasConcept C153911025 @default.
• W2915209213 hasConcept C1629964 @default.
• W2915209213 hasConcept C177504595 @default.
• W2915209213 hasConcept C181199279 @default.
• W2915209213 hasConcept C184235292 @default.
• W2915209213 hasConcept C185592680 @default.
• W2915209213 hasConcept C2776415932 @default.
• W2915209213 hasConcept C55493867 @default.
• W2915209213 hasConcept C57074206 @default.
• W2915209213 hasConcept C86339819 @default.
• W2915209213 hasConcept C86803240 @default.
• W2915209213 hasConcept C87554066 @default.
• W2915209213 hasConcept C97029542 @default.
• W2915209213 hasConceptScore W2915209213C104317684 @default.
• W2915209213 hasConceptScore W2915209213C107538193 @default.
• W2915209213 hasConceptScore W2915209213C11960822 @default.
• W2915209213 hasConceptScore W2915209213C153911025 @default.
• W2915209213 hasConceptScore W2915209213C1629964 @default.
• W2915209213 hasConceptScore W2915209213C177504595 @default.
• W2915209213 hasConceptScore W2915209213C181199279 @default.
• W2915209213 hasConceptScore W2915209213C184235292 @default.
• W2915209213 hasConceptScore W2915209213C185592680 @default.
• W2915209213 hasConceptScore W2915209213C2776415932 @default.
• W2915209213 hasConceptScore W2915209213C55493867 @default.
• W2915209213 hasConceptScore W2915209213C57074206 @default.
• W2915209213 hasConceptScore W2915209213C86339819 @default.
• W2915209213 hasConceptScore W2915209213C86803240 @default.
• W2915209213 hasConceptScore W2915209213C87554066 @default.
• W2915209213 hasConceptScore W2915209213C97029542 @default.
• W2915209213 hasFunder F4320321408 @default.

• next